|
|
|
| Effect of Tanshinone on Th1/Th2 Cytokines in Children with Henoch-Schonlein Purpura and Curative Effect of Tanshinone |
| QI Haihua, HUANG Zhanqiang, HE Lei, et al |
| Affiliated Hospital of Chengde Medical University, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the effect of tanshinone on Th1/Th2 cytokines and therapeutic effect in children with Henoch-Schonlein purpura. Methods: Eighty patients diagnosed with Henoch-Schonlein purpura in our hospital were selected and randomly divided into control group and observation group with 40 cases in each group. Both groups were routinely given symptomatic treatments such as anti-allergic and improving vascular fragility. The group of observation was treated with tanshinone for 2 weeks on the basis of routine treatment. Changes in the levels of INF-γ、IL-2、IL-6、IL-10 in the peripheral blood of the two groups of children before and after therapy was observeed, and the clinical efficacy was evaluated. Results: There was no significant difference in the levels of INF-γ、IL-2、IL-6 and IL-10 between the control and observation groups before treatment (P>0.05). After treatment, the levels of INF-γ and IL-2 in the peripheral blood of the two groups were higher than before, and the levels of IL-6 and IL-10 were lower than before (P<0.05). The increase in peripheral blood INF-γ and IL-2 levels in the observation group was better than that in the control group (P<0.05), and the decrease in peripheral blood IL-10 levels in the observation group was better than that in the control group (P<0.05). The decrease of IL-6 in peripheral blood of the observation group was no different than that of the control group (P>0.05). The effective rate of the observation group was significantly higher than that of the control group, and there was a statistical difference (P<0.05). Conclusion: Tanshinone has a certain clinical effect in the treatment of allergic purpura in children, and its mechanism may act by influencing the levels of peripheral blood cytokines to correct the body's Th1/Th2 immune imbalance.
|
|
|
|
|
|
[1] Tsuruga K,Watanabe S,Oki E,et al.Imbalance towards Th1 pathway predomin ance in purpura nephritis with proteinuria [J].Pediatr Nephrol,2011,26(12):2253~2258.
[2] 唐雪梅.过敏性紫癜病因及免疫发病机制[J].实用儿科临床杂志,2012,27(21):1634~1636.
[3] Hackl A,Becker JU,Korner LM,et al.Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schonlein purpura nephritis:the role of early initiation and therapeutic drug monitoring[J].Pediatr Nephrol,2018,33(4):619~629.
[4] 刘慧颖,姜长涛,冯娟,等.丹参酮类化合物研究进展[J].中国药理学通报,2016,32(12):1643~1647.
[5] 齐海花,黄占强,何磊,等.链球菌感染对儿童过敏性紫癜Th1/Th2失衡及预后的影响[J].中国皮肤性病学杂志,2020,34(10):1131~1133.
[6] 唐兴珈,傅睿,李群,等.过敏性紫癜不同临床表型患儿肠道菌群的差异分析[J].中国免疫学杂志,2021,37(3):339~345.
[7] Li YY,Li CR,Wang GB,et al.Investigation of the change in CD4+ T cell subset in children with Henoch-Schonlein purpura.[J].Rheumatology International,2012,32(12):3785~3792.
[8] 李亚凤,夏海龙.过敏性紫癜患者血清中IL-27、IL-17的表达及意义[J].免疫学杂志,2020,36(4):337~342.
[9] 滕雅娟,张燕,谭志敏,等.丹参酮联合优甲乐对桥本甲状腺炎伴甲状腺功能减退患者免疫功能的影响[J].西部中医药,2019,32(3):102~105.
[10] 简丽红.丹参酮联合抗过敏药物对过敏性紫癜患儿血清细胞因子含量及免疫功能的影响[J].海南医学院学报,2017,23(10):1384~1387.
[11] 邢超,邵美娟,陈慧,等.Th17、Th22/Treg细胞及相关细胞因子在儿童过敏性紫癜患者外周血中变化及意义[J].中国卫生检验杂志,2017,27(10):1432~1434. |
|
|
|
2021, Vol. 27 
